UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in Standard BioTools Inc. (NASDAQ:LAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 80.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 554,203 shares of the company's stock after buying an additional 247,332 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.15% of Standard BioTools worth $970,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in LAB. Geode Capital Management LLC lifted its position in Standard BioTools by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 6,975,221 shares of the company's stock valued at $12,209,000 after buying an additional 25,504 shares during the period. Mirabella Financial Services LLP purchased a new position in Standard BioTools in the 4th quarter worth about $5,478,000. Northern Trust Corp raised its position in Standard BioTools by 9.3% in the 4th quarter. Northern Trust Corp now owns 2,875,160 shares of the company's stock worth $5,032,000 after buying an additional 243,522 shares during the last quarter. Royce & Associates LP grew its stake in shares of Standard BioTools by 136.8% during the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company's stock valued at $2,547,000 after purchasing an additional 840,951 shares during the period. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Standard BioTools by 83.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 296,631 shares of the company's stock valued at $519,000 after purchasing an additional 135,075 shares during the period. 53.74% of the stock is owned by hedge funds and other institutional investors.

Standard BioTools Price Performance

NASDAQ LAB remained flat at $1.05 during trading hours on Friday. The company had a trading volume of 921,713 shares, compared to its average volume of 2,089,444. The business's 50-day moving average is $1.10 and its 200-day moving average is $1.37. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.41. The stock has a market cap of $398.81 million, a P/E ratio of -1.48 and a beta of 1.50.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a research note on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.